Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure

Summary

Phase I trial to determine the dose of imatinib mesylate that is most effective with the least amount of toxic side effects in treating patients who have advanced cancer and kidney failure. Imatinib mesylate may stop the growth of cancer cells by stopping the enzyme necessary for cancer cell growth. Kidney failure may delay the elimination of imatinib mesylate from the body, which may lead to longer drug exposure and increase toxic side effects

Timeline

Start

2001-09

Primary completion

2005-04

Completion

—

Drugs

Indications